India · Delayed Price · Currency is INR Jubilant Ingrevia Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY 2026 saw record revenue and EBITDA, driven by strong specialty chemicals and nutrition growth, with robust outlook for FY 2027 and continued investment in capacity. Net debt and working capital improved, and the company remains confident in achieving 20% EBITDA growth.
-
Specialty chemicals and nutrition segments drove volume and EBITDA growth despite pricing pressures, with strong CDMO pipeline wins and major capacity expansions underway. FTAs and cost initiatives are expected to support margin recovery and market share gains in coming quarters.
-
Q2 and H1 FY26 saw record revenue and volume growth, led by specialty chemicals and robust CDMO pipeline. Margins improved despite pricing pressures, with strong cost controls and new capacity expansions supporting future growth.
-
Specialty and Nutrition segments drove strong Q1 FY26 results, with EBITDA up 29% and PAT up 54% year-on-year. Strategic CapEx, cost optimization, and new export opportunities in Europe position the company for continued growth, with a robust pipeline across key markets.
Fiscal Year 2025
-
Q4 saw strong margin and profit growth, with specialty chemicals and nutrition driving performance. Cost optimization and new capacity ramp-up supported a 153% YoY PAT increase, while CapEx and sustainability initiatives position the company for continued growth.
-
Q3 FY25 saw strong year-on-year growth, led by specialty chemicals and nutrition, with EBITDA up 42% and PAT up 80%. Specialty and nutrition now contribute 62% of revenue and 87% of EBITDA, while new vitamin B3 capacity and major CDMO contracts support future growth.
-
Q2 FY25 saw strong year-on-year and sequential growth, led by specialty chemicals and nutrition, with major CDMO contract wins and improved margins. Export share rose to 48%, and the company remains on track with its Pinnacle 345 growth vision, focusing CapEx on high-value segments.
-
Q1 FY25 saw strong sequential EBITDA growth, led by specialty chemicals and cost initiatives, despite lower overall revenue due to chemical intermediates. Margins in specialty and nutrition segments improved, with robust CDMO growth and positive outlook for all segments in FY25.